BLCO Stock Analysis: Bausch + Lomb | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 6.186m USD | 12M Return: 13.1% | CA0717051076 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.88M
EPS Trend: -41.7%
Qual. Beats: 0
Rev. Trend: 97.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bausch + Lomb Corporation (NYSE: BLCO) is a Canada-headquartered eye health company operating across more than a dozen countries. Founded in 1853 and spun off from Bausch Health Companies Inc., it sits within the GICS Health Care Supplies sub-industry and serves the global ophthalmology and vision care markets through three reporting segments.
The Vision Care segment offers contact lenses across the spectrum of wearing modalities, along with lens care products, eye vitamins, and over-the-counter drops for allergies, conjunctivitis, dry eye, and redness. The Pharmaceuticals segment provides both proprietary and generic products for post-operative care, glaucoma, ocular hypertension, eye inflammation, dry eyes, and retinal diseases. The Surgical segment supplies intraocular lenses, phacoemulsification equipment, and related instruments and consumables used in cataract, corneal, vitreous, and retinal procedures. Products are sold through direct sales forces and independent distributors.
- Alcon and J&J competition pressures daily disposable contact lens share
- Cataract surgical IOL volumes drive Surgical segment revenue growth
- XIPERE retinal drug uptake expands pharmaceutical segment margins
| Net Income: -171.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 2.21 > 1.0 |
| NWC/Revenue: 19.40% < 20% (prev 20.57%; Δ -1.17% < -1%) |
| CFO/TA 0.03 > 3% & CFO 458.4m > Net Income -171.0m |
| Net Debt (4.75b) to EBITDA (742.0m): 6.40 < 3 |
| Current Ratio: 1.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (357.1m) vs 12m ago 0.96% < -2% |
| Gross Margin: 57.23% > 18% (prev 56.94%; Δ 0.29% > 0.5%) |
| Asset Turnover: 38.42% > 50% (prev 35.36%; Δ 3.06% > 0%) |
| Interest Coverage Ratio: 0.84 > 6 (EBIT TTM 331.0m / Interest Expense TTM 396.0m) |
| A: 0.07 (Total Current Assets 2.92b - Total Current Liabilities 1.89b) / Total Assets 13.9b |
| B: -0.07 (Retained Earnings -1.02b / Total Assets 13.9b) |
| C: 0.02 (EBIT TTM 331.0m / Avg Total Assets 13.8b) |
| D: 0.86 (Book Value of Equity 6.38b / Total Liabilities 7.42b) |
| Altman-Z'' = 1.31 = BB |
| DSRI: 0.98 (Receivables 1.16b/1.09b, Revenue 5.32b/4.89b) |
| GMI: 0.99 (GM 56.94% / 57.23%) |
| AQI: 0.98 (AQ_t 0.66 / AQ_t-1 0.67) |
| SGI: 1.09 (Revenue 5.32b / 4.89b) |
| TATA: -0.05 (NI -171.0m - CFO 458.4m) / TA 13.9b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of September 24, 2026, the stock is trading at USD 17.05 with a total of 299,086 shares traded. Over the past week, the price has changed by -0.12%, over one month by -1.56%, over three months by +11.88% and over the past year by +13.06%.
Current recommended Stop Loss: 16.40 (which is 3.8% or 1.4 ATR below the current price).
Bausch + Lomb has received a consensus analysts rating of 3.53. Therefore, it is recommended to hold BLCO.
- StrongBuy: 3
- Buy: 3
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 19 | 11.7% |
P/E Forward = 11.1982
P/S = 1.1619
P/B = 0.9411
P/EG = 0.8878
Revenue TTM = 5.32b USD
EBIT TTM = 331.0m USD
EBITDA TTM = 742.0m USD
Long Term Debt = 5.07b USD (from longTermDebt, last quarter)
Short Term Debt = 43.0m USD (from shortTermDebt, last quarter)
Debt = 5.12b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.75b USD (calculated: Debt 5.12b - CCE 367.0m)
Enterprise Value = 10.9b USD (6.19b + Debt 5.12b - CCE 367.0m)
Interest Coverage Ratio = 0.84 (Ebit TTM 331.0m / Interest Expense TTM 396.0m)
EV/FCF = 77.92x (Enterprise Value 10.9b / FCF TTM 140.3m)
FCF Yield = 1.28% (FCF TTM 140.3m / Enterprise Value 10.9b)
FCF Margin = 2.64% (FCF TTM 140.3m / Revenue TTM 5.32b)
Net Margin = -3.21% (Net Income TTM -171.0m / Revenue TTM 5.32b)
Gross Margin = 57.23% ((Revenue TTM 5.32b - Cost of Revenue TTM 2.27b) / Revenue TTM)
Gross Margin QoQ = 59.11% (prev 56.59%)
Tobins Q-Ratio = 0.79 (Enterprise Value 10.9b / Total Assets 13.9b)
Interest Expense / Debt = 7.74% (Interest Expense 396.0m / Debt 5.12b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 261.5m (EBIT 331.0m * (1 - 21.00%))
Current Ratio = 1.55 (Total Current Assets 2.92b / Total Current Liabilities 1.89b)
Debt / Equity = 0.80 (Debt 5.12b / totalStockholderEquity, last quarter 6.38b)
Debt / EBITDA = 6.40 (Net Debt 4.75b / EBITDA 742.0m)
Debt / FCF = 33.83 (Net Debt 4.75b / FCF TTM 140.3m)
Total Stockholder Equity = 6.41b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.24% (Net Income -171.0m / Total Assets 13.9b)
RoE = -2.67% (Net Income TTM -171.0m / Total Stockholder Equity 6.41b)
RoCE = 2.88% (EBIT 331.0m / Capital Employed (Equity 6.41b + L.T.Debt 5.07b))
RoIC = 2.23% (NOPAT 261.5m / Invested Capital 11.7b)
WACC = 7.39% (E(6.19b)/V(11.3b) * Re(8.44%) + D(5.12b)/V(11.3b) * Rd(7.74%) * (1-Tc(0.21)))
Discount Rate = 8.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.93 | Cagr: 0.76%
[DCF] Terminal Value 75.44% ; FCFF base≈140.3m ; Y1≈140.9m ; Y5≈149.3m
[DCF] Fair Price = N/A (negative equity: EV 2.32b - Net Debt 4.75b = -2.43b; debt exceeds intrinsic value)
EPS Correlation: -41.66 | EPS CAGR: -9.31% | SUE: 0.0 | # QB: 0
Revenue Correlation: 97.71 | Revenue CAGR: 10.43% | SUE: 0.10 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.22 | Chg30d=+1.64% | Revisions=-10% | Analysts=13
EPS current Year (2026-12-31): EPS=0.81 | Chg30d=+0.53% | Revisions=+46% | GrowthEPS=+58.5% | GrowthRev=+7.7%
EPS next Year (2027-12-31): EPS=1.11 | Chg30d=+1.48% | Revisions=+18% | GrowthEPS=+37.2% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: +25% (up=16, down=9)